Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide

References

• WibergKBThe Deuterium isotope effectChem Rev1955554713743
   Web of Science ®Google Scholar
• ParliCJMcMahonREThe mechanism of microsomal deamination: heavy isotope studiesDrug Metab Dispos1973113373414149402
   PubMed Web of Science ®Google Scholar
• MutlibAEGersonRJMeunierPCThe species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in ratsToxicol Appl Pharmacol2000169110211311076702
   PubMed Web of Science ®Google Scholar
• MutlibAEApplication of stable isotope-labeled compounds in metabolism and in metabolism-mediated toxicity studiesChem Res Toxicol20082191672168918702535
   PubMed Web of Science ®Google Scholar
• KatsnelsonAHeavy drugs draw heavy interest from pharma backersNat Med201319665623744136
   PubMed Web of Science ®Google Scholar
• WangYKumarDYangCHanKShaikSTheoretical study of N-demethylation of substituted N,N-dimethylanilines by cytochrome P450: the mechanistic significance of kinetic isotope effect profilesJ Phys Chem B2007111267700771017559261
   PubMed Web of Science ®Google Scholar
• LiCWuWChoKBShaikSOxidation of tertiary amines by cytochrome p450-kinetic isotope effect as a spin-state reactivity probeChemistry200915348492850319322770
   PubMed Web of Science ®Google Scholar
• CernyMAHanzlikRPCytochrome P450-catalyzed oxidation of N-benzyl-N-cyclopropylamine generates both cyclopropanone hydrate and 3-hydroxypropionaldehyde via hydrogen abstraction, not single electron transferJ Am Chem Soc2006128103346335416522116
   PubMed Web of Science ®Google Scholar
• HarbesonSLTungRDDeuterium medicinal chemistry: a new approach to drug discovery and developmentMedchem News20142822
   Google Scholar
• GantTGUsing deuterium in drug discovery: leaving the label in the drugJ Med Chem20145793595361124294889
   PubMed Web of Science ®Google Scholar
• ZhangYTortorellaMDWangYSynthesis of deuterated benzopyran derivatives as selective COX-2 inhibitors with improved pharmacokinetic propertiesACS Med Chem Lett20145101162116625313331
   PubMed Web of Science ®Google Scholar
• StringerRAWilliamsGPicardFApplication of a deuterium replacement strategy to modulate the pharmacokinetics of 7-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-3-(4-methoxy-2-methylphenyl)-2,6-dimethylp yrazolo[5,1-b]oxazole, a novel CRF1 antagonistDrug Metab Dispos201442595496224616265
   PubMed Web of Science ®Google Scholar
• XuRZhanMPengLDesign, synthesis and biological evaluation of deuterated nintedanib for improving pharmacokinetic propertiesJ Labelled Comp Radiopharm201558730831226011584
   PubMed Web of Science ®Google Scholar
• MorganAJNguyenSUttamsinghVDesign and synthesis of deuterated boceprevir analogs with enhanced pharmacokinetic propertiesJ Labelled Comp Radiopharm2011549613624
   Web of Science ®Google Scholar
• GuoSPangXPengLDesign, synthesis and biological evaluation of deuterated Tivozanib for improving pharmacokinetic propertiesBioorg Med Chem Lett201525112425242825908516
   PubMed Web of Science ®Google Scholar
• ShaoLAbolinCHewittMCKochPVarneyMDerivatives of tramadol for increased duration of effectBioorg Med Chem Lett200616369169416257206
   PubMed Web of Science ®Google Scholar
• ZhuYQZhouJJiaoBDeuterated clopidogrel analogues as a new generation of antiplatelet agentsACS Med Chem Lett20134334935224900671
   PubMed Web of Science ®Google Scholar
• UttamsinghVGallegosRLiuJFAltering metabolic profiles of drugs by precision deuteration: reducing mechanism-based inhibition of CYP2D6 by paroxetineJ Pharmacol Exp Ther20153541435425943764
   PubMed Web of Science ®Google Scholar
• GrahamPSabounjianLShipleyJSafety, tolerability and pharmacokinetics of Ctp-499 in a multi-center, double-blind, two-arm, placebo-controlled, randomized study in non-dialysis patients with stage 3 chronic kidney diseaseAm J Kidney Dis2012594A38A38
   Web of Science ®Google Scholar
• BramanVGrahamPChengCFA randomized phase I evaluation of CTP-499, a novel deuterium-containing drug candidate for diabetic nephropathyClin Pharmacol Drug Dev201321536627121560
   PubMed Web of Science ®Google Scholar
• TestaCStamlerDFrankSTesting the safety and efficacy of SD-809 for symptomatic treatment of chorea in Huntington diseaseNeurotherapeutics2014111222223
   Web of Science ®Google Scholar
• TranCOukSCleggNJDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancerScience2009324592878779019359544
   PubMed Web of Science ®Google Scholar
• ScherHIFizaziKSaadFAFFIRM InvestigatorsIncreased survival with enzalutamide in prostate cancer after chemotherapyN Engl J Med2012367131187119722894553
   PubMed Web of Science ®Google Scholar
• NingYMPierceWMaherVEEnzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. Food and Drug Administration drug approval summaryClin Cancer Res201319226067607324141628
   PubMed Web of Science ®Google Scholar
• BeerTMArmstrongAJRathkopfDEEnzalutamide in metastatic prostate cancer before chemotherapyN Engl J Med2014371542443324881730
   PubMed Web of Science ®Google Scholar
• NingYMBraveMMaherVEU.S. Food and Drug Administration approval summary: enzalutamide for the treatment of patients with chemotherapy-naive metastatic castration-resistant prostate cancerOncologist201520896096626070917
   PubMed Web of Science ®Google Scholar
• Astellas Pharma US, Inc. [webpage on the Internet]XTANDI^® (enzalutamide) Capsules for Oral Use2012 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdfAccessed September 23, 2013
   Google Scholar
• GibbonsJAOuatasTKrauwinkelWClinical pharmacokinetic studies of enzalutamideClin Pharmacokinet201554101043105525917876
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals and Medical Devices Agency [webpage on the Internet]mdv3100 Available from: http://ss.pmda.go.jp/ja_all/search.x?q=mdv3100&x=32&y=10&ie=UTF-8&page=1Accessed April 13, 2016
   Google Scholar
• SchofieldJBrasseurDde BruinBEffect of deuteration on the metabolism and clearance of some pharmacologically active compounds – synthesis and in vitro metabolism of deuterated derivatives of dronedadroneJ Labelled Comp Radiopharm2013569–1050451224285529
   PubMed Web of Science ®Google Scholar
• XuGLvBHRobergeJYDesign, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetesJ Med Chem20145741236125124456245
   PubMed Web of Science ®Google Scholar
• SharmaRStrelevitzTJGaoHDeuterium isotope effects on drug pharmacokinetics I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugsDrug Metab Dispos201240362563422190693
   PubMed Web of Science ®Google Scholar
• DunsaedCDornishJAastveitTPettersenEIn vivo pharmacokinetics of the antitumor agent 4,6-benzylidene-d-glucose (bg) and a deuterated analog 4,6-benzylidene-d1-d-glucose (p-1013) in mice, rats and dogsInt J Oncol199321616621573515
   PubMed Web of Science ®Google Scholar
• HelfenbeinJLartigueCNoiraultEIsotopic effect study of propofol deuteration on the metabolism, activity, and toxicity of the anestheticJ Med Chem200245265806580812477364
   PubMed Web of Science ®Google Scholar
• ManleyPWBlascoFMestanJAichholzRThe kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588Bioorg Med Chem201321113231323923611771
   PubMed Web of Science ®Google Scholar